FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Periodontal Disease Treatment After Stroke or Transient Ischemic Attack: The PREMIERS Study, a Randomized Clinical Trial. PMID 37548008 · Stroke · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients. PMID 37540921 · Eur J Cancer · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. PMID 37536351 · Lancet Child Adolesc Health · 2023-Sep The trial meets criteria for oncology, human, randomized, time-to-event endpoint, drug intervention, and original result. However, the trial phase is not explicitly reported in the provided text. The metadata 'deterministic_review' notes that phase is not confirmed and requires review. Since the phase cannot be established from the provided evidence, the 'phase3_or_definitive' criterion is null, making the record ineligible. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| CARE: Protocol of a randomised trial evaluating the feasibility of preoperative intentional weight loss to support postoperative recovery in patients with excess weight and colorectal cancer. PMID 37525408 · Colorectal Dis · 2023-Sep This is a protocol for a randomized feasibility trial in colorectal cancer patients, not a Phase III/IIIb or Phase II/III randomized trial reporting results. The intervention is a non-drug weight loss program. The primary outcome is 30-day postoperative morbidity, not a time-to-event efficacy endpoint like OS, PFS, etc. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Correction: Three-year survival and distribution of lymph node metastases in gastric cancer following neoadjuvant chemotherapy: results from a European randomized clinical trial. PMID 37516694 · Surg Endosc · 2023-Sep The record is a 'Published Erratum', which is not a primary report of trial results. The title mentions a 'European randomized clinical trial' and 'survival', suggesting oncology, human, randomized, and drug intervention. However, without the abstract or full text, the phase (III/IIIb or II/III), the primary/key secondary time-to-event endpoint, and whether it is an original result cannot be confirmed. The erratum likely modifies a previous publication, but the original report's status is unknown. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers. PMID 37506588 · Eur J Cancer · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Prospective randomized clinical studies involving reirradiation: update of a systematic review. PMID 37500926 · Strahlenther Onkol · 2023-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial. PMID 37497730 · Clin Exp Rheumatol · 2023-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| ConquerFear-Group: A randomized controlled trial of an online-delivered group-based psychological intervention for fear of cancer recurrence in breast cancer survivors. PMID 37489745 · Psychooncology · 2023-Sep The record describes a randomized controlled trial of a psychological intervention (ConquerFear-Group) for fear of cancer recurrence in breast cancer survivors. It is an oncology study in humans and is randomized. However, it lacks a drug-containing intervention (the intervention is online group-based psychological therapy vs. relaxation training). Furthermore, the primary endpoint is Fear of Cancer Recurrence Inventory (FCRI) total score, a patient-reported outcome, not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or an endpoint typically analyzed with Kaplan-Meier or HR. Therefore, it does not meet the core inclusion criteria for this adjudication. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial. PMID 37482012 · Eur J Cancer · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials. PMID 37473517 · Cancer Treat Rev · 2023-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial. PMID 37473466 · Eur J Cancer · 2023-Sep The record is eligible on all criteria except the trial phase, which is not explicitly stated in the provided metadata (e.g., as 'Phase III' or 'Phase II/III'). The deterministic review correctly flags this as 'phase3_evidence_unclear'. Therefore, is_eligible is set to null. Confidence is moderate as all other criteria are met. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Three-year survival and distribution of lymph node metastases in gastric cancer following neoadjuvant chemotherapy: results from a European randomized clinical trial. PMID 37468751 · Surg Endosc · 2023-Sep This is a secondary analysis of a randomized trial comparing surgical techniques for gastric cancer, with a drug intervention (neoadjuvant chemotherapy) but it does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS with Kaplan-Meier or HR). The 3-year survival is reported as a percentage, not as a time-to-event analysis. The trial phase is not explicitly stated as Phase III. Therefore, it does not meet all required criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia. PMID 37465924 · Immunotherapy · 2023-Sep Cannot confirm that the pooled analysis represents the original formal result report of a Phase III/IIIb or Phase II/III trial. The abstract states data are pooled from three studies but does not specify their individual phases or confirm that this pooled analysis is the primary/definitive report for any single trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Preoperative mechanical bowel preparation using conventional versus hyperosmolar polyethylene glycol-electrolyte lavage solution before laparoscopic resection for colorectal cancer (TLUMP test): a phase III, multicenter randomized controlled non-inferiority trial. PMID 37462794 · J Gastroenterol · 2023-Sep 干预为非药物单独策略,未满足药物干预要求。 |
H
L
B
|
旧查询独有 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. PMID 37454537 · Eur J Cancer · 2023-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091). PMID 37453240 · Eur J Cancer · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| General anesthesia combined with bilateral 2-level erector spinae plane block may accelerate postoperative gastrointestinal function recovery and rehabilitation process in patients undergoing posterior lumbar surgery: A randomized controlled trial. PMID 37429768 · Surgery · 2023-Sep The study is a randomized controlled trial in humans, but it is not oncology-focused, does not involve a drug intervention as the primary treatment, and does not use a standard oncology time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Trends in participant race and sex reporting in lung cancer phase III clinical trials. PMID 37421166 · Cancer Rep (Hoboken) · 2023-Sep The record is an epidemiological analysis of demographic trends in prior phase III trials, not an original trial report with efficacy results. It lacks a drug intervention, randomization comparison, and any time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer. PMID 37418031 · Breast Cancer Res Treat · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). PMID 37414705 · Eur Urol · 2023-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Study protocol for a multicenter randomized controlled trial to compare radiofrequency ablation with surgical resection for treatment of pancreatic insulinoma. PMID 37407318 · Dig Liver Dis · 2023-Sep 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy of mindfulness-based relapse prevention in a sample of veterans in a substance use disorder aftercare program: A randomized controlled trial. PMID 37364669 · J Subst Use Addict Treat · 2023-Sep The study is a randomized controlled trial of a mindfulness-based intervention for substance use disorder in veterans. It does not involve human malignant neoplasms (cancer), does not test a drug-containing intervention, and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis. The MeSH term 'Neoplasm Recurrence, Local' appears to be an indexing error unrelated to the study's actual focus on substance use relapse. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). PMID 37355526 · Breast Cancer Res Treat · 2023-Sep This is a preplanned analysis of clinical practice heterogeneity within a Phase III randomized trial, focusing on the use of neoadjuvant systemic therapy. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) for a drug intervention. Therefore, it is not an eligible original formal-result report of a trial efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A comparison of concurrent chemoradiotherapy and radical surgery in patients with specific locally advanced cervical cancer (stage IB3, IIA2, IIICr): trial protocol for a randomized controlled study (C-CRAL trial). PMID 37350146 · J Gynecol Oncol · 2023-Sep 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| [18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study. PMID 37341747 · Eur J Nucl Med Mol Imaging · 2023-Sep The study is a randomized, open-label, cross-over diagnostic imaging trial comparing detection rates of two radiopharmaceuticals ([18F]DCFPyL vs [18F]fluoromethylcholine) in prostate cancer biochemical recurrence. The primary endpoint is detection rate, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The study does not involve a therapeutic drug intervention; the agents are diagnostic imaging tracers. Therefore, it does not meet the inclusion criteria for a therapeutic oncology trial with time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Distal Versus Total D2-Gastrectomy for Gastric Cancer: a Secondary Analysis of Surgical and Oncological Outcomes Including Quality of Life in the Multicenter Randomized LOGICA-Trial. PMID 37340107 · J Gastrointest Surg · 2023-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Identification of prognostic melatonin-related lncRNA signature in tumor immune microenvironment and drug resistance for breast cancer. PMID 37330302 · Asian J Surg · 2023-Sep The study is a retrospective bioinformatics analysis of publicly available data to develop a prognostic signature. It is not a Phase III/IIIb or Phase II/III randomized clinical trial of a drug intervention with a primary/key secondary time-to-event efficacy endpoint. The publication type is mislabeled as 'Randomized Controlled Trial' but refers only to data splitting for model training/validation, not a clinical trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant hepatic artery infusion pump chemotherapy for resected colorectal cancer liver metastases. PMID 37321884 · Surgery · 2023-Sep The record is a review or commentary, not an original formal-result report of a single randomized trial. It discusses multiple trials but does not present primary data from one specific Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Three-Course Neoadjuvant Chemotherapy Associated with Unfavorable Survival of Non-responders to the First Two Courses for Locally Advanced Esophageal Cancer. PMID 37316744 · Ann Surg Oncol · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. PMID 37308218 · Ann Rheum Dis · 2023-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation. PMID 37301257 · Transplant Cell Ther · 2023-Sep The study is a retrospective analysis of real-world data comparing two GVHD prophylaxis regimens in patients undergoing HSCT. While it is randomized in the sense of comparing two groups, the intervention is not a primary anti-cancer drug regimen but rather supportive care (GVHD prophylaxis). The study does not meet the requirement for a drug-containing intervention targeting the malignant neoplasm itself. Furthermore, the design is not a prospectively randomized Phase III trial; it is an observational study using a historical control cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel. PMID 37290911 · Prostate · 2023-Sep The record is a pooled, secondary analysis of multiple trials, not the primary, formal-result report of a single Phase III/IIIb or Phase II/III randomized trial. While the constituent trials likely included a drug intervention (docetaxel) and reported time-to-event data, this specific publication does not present the original trial results required for eligibility. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial. PMID 37289335 · Clin Exp Nephrol · 2023-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Telephone monitoring and 15-month outcomes for patients with co-occurring substance use and mental health disorders: Moderating effects of high-risk patient characteristics. PMID 37285924 · J Subst Use Addict Treat · 2023-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder cancer: comparison of logistic regression and artificial neural network: a SEER population-based study. PMID 37280316 · Int Urol Nephrol · 2023-Sep The record is a retrospective, population-based observational study using the SEER database to compare predictive models (logistic regression vs. neural network) for survival in bladder cancer. It is not a randomized controlled trial of a drug intervention. While it is an original result with time-to-event endpoints (CSS, OS), it fails the core eligibility criteria: it is not a Phase III/IIIb or Phase II/III randomized trial and does not involve a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hemostatic Powder vs Standard Endoscopic Treatment for Gastrointestinal Tumor Bleeding: A Multicenter Randomized Trial. PMID 37277078 · Gastroenterology · 2023-Sep The study is a randomized trial for GI tumor bleeding with a primary time-to-event endpoint (rebleeding). However, the intervention (TC-325 hemostatic powder) is a device, not a drug, and the trial phase is not specified as Phase III/IIIb or Phase II/III, which are required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of High-Versus Low-Frequency of Abdominopelvic Computed Tomography Follow-Up Testing on Overall Survival in Patients With Stage II Or III Colon Cancer. PMID 37271592 · Clin Colorectal Cancer · 2023-Sep The study is a retrospective, observational analysis of surveillance frequency in colon cancer, not a randomized controlled trial of a drug intervention. It lacks the required trial phase, randomization, and drug intervention criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Construction and validation of a SEER-based prognostic nomogram for young and middle-aged males patients with hepatocellular carcinoma. PMID 37266663 · J Cancer Res Clin Oncol · 2023-Sep The record is an oncology study on hepatocellular carcinoma with a time-to-event endpoint (overall survival) and randomized data splitting, but it is ineligible because it lacks a drug-containing intervention and is not a Phase III/IIIb or Phase II/III randomized trial of a therapeutic agent. It is a retrospective prognostic nomogram study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Metabolomics-Based Biomarker for Dietary Fat and Associations with Chronic Disease Risk in Postmenopausal Women. PMID 37245660 · J Nutr · 2023-Sep The record is an observational, biomarker-based analysis of a randomized trial cohort studying dietary fat patterns, not a drug intervention. While it is a human, randomized study with time-to-event endpoints (OS, cancer incidence), it does not meet the core eligibility criterion of a drug-containing intervention in a Phase III/IIIb or Phase II/III randomized trial. The original trial is a dietary modification RCT, and this is a secondary analysis using that cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Do patients with metastatic renal cell carcinoma obtain survival benefits from cytoreductive nephrectomy? A population-based study. PMID 37231275 · J Cancer Res Clin Oncol · 2023-Sep The study is a retrospective population-based cohort analysis using SEER data to develop prognostic nomograms, not a randomized controlled trial testing a drug intervention in a specific phase. The 'randomized' designation in metadata refers to random splitting of data for model validation, not trial randomization. It lacks a drug-containing intervention arm and Phase III trial evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Defining a Nomogram for Predicting Early Recurrence in Gastric Cancer Patients After Neoadjuvant Chemotherapy and Radical Gastrectomy. PMID 37221389 · J Gastrointest Surg · 2023-Sep The study is a retrospective analysis of a cohort from a randomized trial, but the primary analysis presented is for a predictive nomogram for early recurrence, not the efficacy of a drug intervention from the original randomized trial. The phase of the underlying trial is not specified. It is not a primary result report of the drug intervention's efficacy from a Phase III or II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Development and Validation of a Machine-Learning Model to Predict Early Recurrence of Intrahepatic Cholangiocarcinoma. PMID 37210452 · Ann Surg Oncol · 2023-Sep The record describes the development and validation of a machine-learning model for predicting early recurrence of intrahepatic cholangiocarcinoma after surgery. It is not a report of a randomized clinical trial evaluating a drug intervention with a primary time-to-event efficacy endpoint. The 'Randomized Controlled Trial' publication type is incorrect for this study, which is a retrospective prognostic model analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Loren K. Mell, Stephanie L. Pugh, Christopher U. Jones, et al. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.01.020. PMID 37202316 · Eur Urol · 2023-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis. PMID 37193776 · Prostate Cancer Prostatic Dis · 2023-Sep The study is an interim analysis of a randomized trial for a diagnostic test (ExoDx Prostate EPI) in prostate cancer. While it is oncology-related, human, and randomized, it lacks a drug intervention (the intervention is a urine test) and does not evaluate a standard time-to-event efficacy endpoint (e.g., OS, PFS). The outcomes assessed (biopsy rates, time to biopsy, incidence of high-grade prostate cancer) are diagnostic/clinical utility endpoints, not therapeutic time-to-event endpoints suitable for KM digitization in this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503. PMID 37126140 · Qual Life Res · 2023-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group. PMID 37118612 · Ann Surg Oncol · 2023-Sep The record describes an analysis of resectability assessments from the CAIRO5 trial, which is a randomized phase III trial in oncology. However, the abstract does not present a time-to-event efficacy endpoint (OS, PFS, etc.) for a drug intervention. It reports on intersurgeon variability in treatment planning, which is a secondary analysis of decision-making processes, not the primary efficacy analysis of a drug. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nomograms for predicting overall survival and cancer-specific survival in patients with invasive micropapillary carcinoma: Based on the SEER database. PMID 36933963 · Asian J Surg · 2023-Sep The study is an oncology, human, retrospective prognostic model development paper that analyzes time-to-event endpoints (OS, CSS). However, it does not meet the core eligibility criteria: it is not a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention. The 'randomized' signal refers to the random split of patients into training/validation cohorts, not a randomized trial of a drug. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Narrow-Band Imaging in Transoral Laser Surgery for Early Glottic Cancer: A Randomized Controlled Trial. PMID 36821814 · Otolaryngol Head Neck Surg · 2023-Sep The study is a randomized trial in human oncology reporting a time-to-event endpoint (recurrence-free survival). However, it is excluded because the phase is not explicitly established as Phase III/IIIb or Phase II/III, and the intervention is a non-drug technique (narrow-band imaging during transoral laser surgery), not a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study. PMID 36807048 · BMJ Support Palliat Care · 2023-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |